8-KMaterial AgreementsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Feb 24, 2006)

Filed February 24, 2006For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant development in its influenza program through an Addendum to its existing Research Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. This agreement, effective December 13, 2005, expands the collaboration to focus specifically on the discovery and development of RNAi therapeutics for pandemic influenza. This partnership leverages Alnylam's RNA interference technology with Novartis's expertise in drug development, aiming to address a critical unmet medical need. Investors should view this as a strategic move by Alnylam to advance its pipeline and potentially generate future revenue streams through collaboration with a major pharmaceutical player. The focus on pandemic flu indicates a high-impact therapeutic area, and the involvement of Novartis suggests validation of Alnylam's technology and a commitment to its development. Further details on the terms of the collaboration, including financial considerations and milestones, are expected to be outlined in the referenced Addendum filed as an exhibit.

Key Highlights

  • 1Alnylam Pharmaceuticals entered into an Addendum to its Research Collaboration and License Agreement with Novartis.
  • 2The Addendum focuses on the discovery and development of RNAi therapeutics for pandemic flu.
  • 3The agreement is effective as of December 13, 2005.
  • 4This collaboration supplements and modifies the original agreement dated October 12, 2005.
  • 5The partnership leverages Alnylam's RNAi technology and Novartis's development capabilities.
  • 6This represents a strategic expansion of Alnylam's influenza program.

Frequently Asked Questions

The primary purpose of the Addendum is to establish a focused collaboration between Alnylam and Novartis on the discovery and development of RNAi therapeutics specifically for pandemic influenza.

The Addendum supplements and, in relevant parts, supersedes the original Research Collaboration and License Agreement dated October 12, 2005. It modifies the scope to concentrate on the pandemic flu program.

Focusing on pandemic flu is significant as it addresses a critical global health threat with a substantial unmet medical need. Success in this area could lead to significant commercial opportunities and a strong positive impact on public health.

More detailed information regarding the terms of the Addendum is available in Exhibit 10.1, which is attached to this 8-K filing and incorporated by reference.